Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $60 | $42 | $35 | $30 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $61 | $44 | $37 | $32 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 61.4% | 30.2% | 0.2% | – |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 84.2% | 81.5% | 88% | 82.7% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 23.8% | 2.4% | 1.9% | -23.8% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 20.1% | -8.6% | -9.7% | -14.1% |
| EPS Diluted | 1.84 | -0.51 | -0.44 | -0.65 |
| % Growth | 460.8% | -15.9% | 32.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |